Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › lenvatinib

lenvatinib

25 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of lenvatinib

59 trials tracked of lenvatinib: 18 in phase 3 or 4 and 14 with published results. The most-cited published study has 461 citations.

59Trials tracked
18Phase 3 & 4
0Recruiting
14With published results
Phase distribution
Phase 3 18 Phase 2 32 Phase 1 9
  1. Phase 3 Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002) Completed · 461 cited
  2. Phase 3 Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician's Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) Completed · 156 cited
  3. Phase 3 A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma Completed · 149 cited
  4. Phase 3 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC) Completed · 104 cited
  5. Phase 3 Study of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017) Completed · 95 cited
  6. Phase 3 Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011) Completed · 81 cited
Show 44 more trials
  1. Phase 3 Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007) Completed · 78 cited
  2. Phase 3 Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008) Completed · 78 cited
  3. Phase 3 A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010) (KEYNOTE-010) Completed · 78 cited
  4. Phase 3 Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) Completed · 71 cited
  5. Phase 3 Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study Completed · 56 cited
  6. Phase 3 Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015) Completed · 24 cited
  7. Phase 3 Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006) Completed · 13 cited
  8. Phase 3 Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003) Completed · 10 cited
  9. Phase 3 Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study Completed
  10. Phase 3 Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study Completed
  11. Phase 3 Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study Completed
  12. Phase 3 A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (MK-7902-010/LEAP-010)-China Extension Completed
  13. Phase 2 Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma Completed
  14. Phase 2 A Trial of Lenvatinib (E7080) in Subjects With Iodine-131 Refractory Differentiated Thyroid Cancer to Evaluate Whether an Oral Starting Dose of 18 Milligram (mg) Daily Will Provide Comparable Efficacy to a 24 mg Starting Dose, But Have a Better Safety Profile Completed
  15. Phase 2 A Study Comparing the Combination of the Best Supportive Care Plus E7080 Versus Best Supportive Care Alone, in Patients With Advanced Lung Cancer or Lung Cancer That Has Spread, Who Have Been Previously Treated, Unsuccessfully, With at Least 2 Different Treatments Completed
  16. Phase 2 An Open-Label, 2-Cohort, Multicenter, Study of Lenvatinib in Previously Treated Subjects With Unresectable Stage III or Stage IV Melanoma Completed
  17. Phase 2 To Evaluate the Efficacy and Safety of Tislelizumab in Combination With Lenvatinib in Participants With Selected Solid Tumors Completed
  18. Phase 2 Lenvatinib in Treating Patients With Metastatic or Advanced Pheochromocytoma or Paraganglioma That Cannot Be Removed by Surgery Completed
  19. Phase 2 A Study of E7080 Alone, and in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Renal Cell Carcinoma Following One Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Treatment Completed
  20. Phase 2 Lenvatinib Efficacy in Metastatic Neuroendocrine Tumors Completed
  21. Phase 2 A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma Completed
  22. Phase 2 Study of Lenvatinib in Subjects With Advanced Endometrial Cancer and Disease Progression Completed
  23. Phase 2 E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma Completed
  24. Phase 2 Trial to Assess Safety and Efficacy of Lenvatinib (18 mg vs. 14 mg) in Combination With Everolimus in Participants With Renal Cell Carcinoma Completed
  25. Phase 2 Lenvatinib and Eribulin in Advanced Soft Tissue Sarcoma Completed
  26. Phase 2 Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) Completed
  27. Phase 2 Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009/E7080-G000-228/LEAP-009) Completed
  28. Phase 2 Study of the Safety and Activity of Lenvatinib (E7080) in Subjects With KIF5B-RET-Positive Adenocarcinoma of the Lung Completed
  29. Phase 2 Lenvatinib and Pembrolizumab Simultaneous Combination Study Completed
  30. Phase 2 Study of Lenvatinib (E7080) in Participants With Advanced Hepatocellular Carcinoma (HCC) Completed
  31. Phase 2 A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors Completed
  32. Phase 2 A Study in Subjects With Recurrent Malignant Glioma Completed
  33. Phase 2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults With Osteosarcoma Completed
  34. Phase 2 A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080) Completed
  35. Phase 2 Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) Completed
  36. Phase 2 A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors Completed
  37. Phase 2 A Phase II a Study of Lenvatinib, a Multi-targeted Tyrosine Kinase Inhibitor, Combined With Pembrolizumab (PD-1 Inhibitor) for the Treatment of Metastatic Gastroesophageal Cancer Patients Who Have Progressed on First or Subsequent Line Therapies Completed
  38. Phase 2 A Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination With Everolimus in Subjects With Unresectable Advanced or Metastatic Non Clear Cell Renal Cell Carcinoma (nccRCC) Who Have Not Received Any Chemotherapy for Advanced Disease Completed
  39. Phase 2 Study of Lenvatinib (E7080) in Unresectable Biliary Tract Cancer (BTC) Who Failed Gemcitabine-based Combination Chemotherapy Completed
  40. Phase 2 Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61) Completed
  41. Phase 2 Eribulin and Lenvatinib in Advanced Solid Tumors Completed
  42. Phase 2 Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004) Completed
  43. Phase 2 Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors Completed
  44. Phase 2 Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors Completed

Showing the 50 most-cited and recently-updated of 59 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Early genomic profiling optimizes treatment selection and expands precision therapy options across thyroid cancer subtypes
Diabetes & Endocrinology Guideline
Early genomic profiling optimizes treatment selection and expands precision therapy options across thyroid cancer subtypes Targeted therapies expand options for advanced thyroid cancer
This narrative review discusses molecular profiling and targeted therapies for patients with advanced, recurrent, or radioiodine-refractory …
New review shows molecular profiling can unlock more personalized treatments for people with advanced thyroid cancer.
Frontiers Jun 6, 2026
Lenvatinib plus PD-1 inhibitor improves survival versus bevacizumab plus PD-1 inhibitor in unresectable hepatocellular carcinoma
Oncology Meta-analysis
Lenvatinib plus PD-1 inhibitor improves survival versus bevacizumab plus PD-1 inhibitor in unresectable hepatocellular carcinoma Meta-analysis shows lenvatinib-based regimens improve survival for unresectable liver cancer in East Asia
This systematic review and meta-analysis evaluated first-line treatment for unresectable hepatocellular carcinoma in East Asian populations.
A meta-analysis of East Asian patients with unresectable liver cancer found lenvatinib-based regimens improved survival compared to bevacizu…
Jun 4, 2026
Network meta-analysis finds similar overall survival for three HCC regimens
Oncology Meta-analysis
Network meta-analysis finds similar overall survival for three HCC regimens Three drugs show similar survival for unresectable liver cancer patients
A network meta-analysis of 11 studies in unresectable hepatocellular carcinoma found no statistically significant differences in overall sur…
Three drugs show similar survival for unresectable liver cancer patients, offering patients clearer choices without proving one option is de…
Jun 4, 2026
Bayesian network meta-analysis of first-line immunotherapy versus TKI for advanced hepatocellular carcinoma
Allergy & Immunology Meta-analysis
Bayesian network meta-analysis of first-line immunotherapy versus TKI for advanced hepatocellular carcinoma Immunotherapy Outperforms Standard Care for Advanced Liver Cancer
This Bayesian network meta-analysis of 7,301 patients with advanced hepatocellular carcinoma synthesized evidence from randomized trials. It…
A new analysis of 10 clinical trials shows that immunotherapy drugs help people with advanced liver cancer live longer than standard treatme…
Frontiers May 14, 2026
Zimberelimab plus lenvatinib showed immune rechallenge effects in 30 patients with advanced cervical cancer
OB/GYN & Women's Health Phase II
Zimberelimab plus lenvatinib showed immune rechallenge effects in 30 patients with advanced cervical cancer Small trial finds immune rechallenge may help some advanced cervical cancer patients
This multicenter, single-arm, phase II trial evaluated combined zimberelimab and lenvatinib in 30 patients with advanced cervical cancer who…
A small study of 30 patients suggests combining zimberelimab and lenvatinib after prior treatment might help some with advanced cervical can…
May 1, 2026
HBV-positive status linked to higher surgical conversion in unresectable HCC receiving triple therapy
Allergy & Immunology Cohort
HBV-positive status linked to higher surgical conversion in unresectable HCC receiving triple therapy HBV-positive linked to better outcomes in liver cancer triple therapy
This single-center retrospective cohort study evaluated triple therapy with TACE, lenvatinib, and PD-1 inhibitors in 190 patients with initi…
In unresectable liver cancer, triple therapy with TACE, lenvatinib, and PD-1 inhibitors worked better in HBV-positive patients, a small retr…
Frontiers Apr 24, 2026
Pilot study reports 60.0% conversion rate with lenvatinib, envafolimab, and TACE in hepatocellular carcinoma
Allergy & Immunology Cohort
Pilot study reports 60.0% conversion rate with lenvatinib, envafolimab, and TACE in hepatocellular carcinoma New Liver Cancer Combo Makes Surgery Possible for More Patients
This prospective pilot study enrolled 15 patients with Barcelona Clinic Liver Cancer stage B or C unresectable hepatocellular carcinoma.
This new treatment plan turns advanced liver cancer into operable disease for many patients.
Frontiers Apr 22, 2026
Envafolimab plus lenvatinib and paclitaxel shows activity in advanced gastric cancer after first-line progression
Oncology Phase II
Envafolimab plus lenvatinib and paclitaxel shows activity in advanced gastric cancer after first-line progression New Drug Combo Gives Hope for Late-Stage Stomach Cancer
This phase II, single-center, open-label trial evaluated envafolimab combined with lenvatinib and albumin-bound paclitaxel in 30 patients wi…
Imagine a patient who has already tried every standard treatment available.
Apr 21, 2026
Real-world analysis finds 34% grade 3-4 adverse events in mRCC patients on immune-based combos
Nephrology Cohort
Real-world analysis finds 34% grade 3-4 adverse events in mRCC patients on immune-based combos Kidney Cancer Treatment: Real-World Side Effects Are Less Severe Than Expected
A retrospective cohort analysis of 2,401 patients with metastatic renal cell carcinoma receiving first-line immune-based combination therapy…
Real-world kidney cancer patients experience fewer severe side effects from immunotherapy than clinical trials suggest, offering relief to t…
Frontiers Apr 21, 2026
Immune checkpoint inhibitor regimens improve survival versus tyrosine kinase inhibitor monotherapies in advanced hepatocellular carcinoma
Gastroenterology Meta-analysis
Immune checkpoint inhibitor regimens improve survival versus tyrosine kinase inhibitor monotherapies in advanced hepatocellular carcinoma The Liver Cancer Treatment That Works Better Depending on Your History
This systematic review and meta-analysis of seventeen studies evaluated immune checkpoint inhibitor (ICI)-based regimens versus tyrosine kin…
Immunotherapy beats older drugs for advanced liver cancer, especially when hepatitis B caused the disease, but benefits depend on your liver…
Apr 14, 2026
SBRT plus PD-1 inhibitor and lenvatinib improved PFS in oligoprogressive HCC patients
Gastroenterology Phase II
SBRT plus PD-1 inhibitor and lenvatinib improved PFS in oligoprogressive HCC patients Radiation Plus Immune Drugs Stops Liver Cancer Growth
This prospective Phase 2 study evaluated stereotactic body radiation therapy (SBRT) combined with continued first-line PD-1 inhibitor-based …
Combining targeted radiation with ongoing immune therapy can restart cancer control in patients whose disease was slowly spreading again.
Apr 12, 2026
Envafolimab plus lenvatinib and capecitabine shows activity in resected biliary tract cancer
Oncology Phase II
Envafolimab plus lenvatinib and capecitabine shows activity in resected biliary tract cancer Combination therapy shows promise for preventing biliary tract cancer recurrence after surgery
A single-arm phase II trial in 28 patients with resected biliary tract cancer at high risk of recurrence found median disease-free survival …
A new three-drug combination helped 68% of high-risk biliary tract cancer patients stay cancer-free for a year after surgery, with 91% still…
Apr 2, 2026